The patient, a man in his mid-50s, had no previous noteworthy medical history and received treatment at the University of California, San Francisco.
“After one week of nitroxoline treatment, MRI showed decreased size of the cerebral abscesses and no new lesions compared with MRI before nitroxoline,” researchers who treated the patient wrote.
Post-discharge, the patient’s lesions continued to show improvement. Now 15 months out, he regularly takes nitroxoline as well as other medications, but has been able to continue life in his community with assistance from family members.
“Repurposed use of nitroxoline associated with survival from B. mandrillaris GAE demonstrates the potential of basic research to identify antiamebic agents that improve outcome of this rare and deadly disease,” researchers noted.
Other researchers not affiliated with the care or published findings have cited the case as “a breakthrough in treating a brain infection that’s long been presumed to be a death sentence,” they told Science.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.